Literature DB >> 9923859

Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.

Y C Xie1, C Hwang, W Overwijk, Z Zeng, M H Eng, J J Mulé, M J Imperiale, N P Restifo, M G Sanda.   

Abstract

BACKGROUND: Evidence that simian virus 40 (SV40) is associated with human mesotheliomas, osteosarcomas, and brain tumors suggests that a recombinant vaccine directed against lethal cancers expressing SV40 T antigen (Tag) could have clinical utility. To address this potential need, we designed a novel vaccinia virus construct that encodes an SV40 Tag in which oncogenic domains were excluded and immunogenic domains were preserved. We named this recombinant construct vaccinia-encoding safety-modified SV40 Tag (vac-mTag).
METHODS: Purified vac-mTag was characterized by DNA sequencing, reverse transcription-coupled polymerase chain reaction, western blot analysis, and immunocytochemical techniques. Induction of Tag-specific immunity was examined by cytolytic T-cell assays, and the efficacy of vac-mTag in protecting animals against Tag-expressing tumors and in treating pre-established microscopic tumors was evaluated in vac-mTag-immunized BALB/c mice.
RESULTS: The immune response elicited by vac-mTag in C57BL/6 and BALB/c mice included an SV40 Tag-specific cytolytic T-lymphocyte activity against syngeneic (identical genetic background) SV40 Tag-expressing tumor targets. Immunization of mice with a single dose of vac-mTag resulted in potent protection against subsequent challenge with a lethal mouse cancer expressing SV40 Tag. In addition, single-dose vac-mTag immunization coadministered with interleukin 2 produced a possible therapeutic effect against a preadministered microscopic (but lethal) burden of Tag-expressing tumor cells in vivo.
CONCLUSION: vac-mTag induces an effective immune response in mice that is specific for a tumor-associated antigen. This response protects against a lethal tumor challenge and results in a possible therapeutic effect against Tag-expressing tumors in vivo. Thus, vac-mTag provides a new avenue for the development of therapies for human cancers thought to be associated with SV40.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9923859      PMCID: PMC2249695          DOI: 10.1093/jnci/91.2.169

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  32 in total

Review 1.  Human exposure to SV40: review and comment.

Authors:  K Shah; N Nathanson
Journal:  Am J Epidemiol       Date:  1976-01       Impact factor: 4.897

2.  Nuclear preparations of SV40-transformed cells contain tumor-specific transplantation antigen activity.

Authors:  J L Anderson; R G Martin; C Chang; P T Mora; D M Livingston
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

Review 3.  SV40 and human brain tumors.

Authors:  E Geissler
Journal:  Prog Med Virol       Date:  1990

Review 4.  Vaccinia virus: a tool for research and vaccine development.

Authors:  B Moss
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

5.  A DNA replication-positive mutant of simian virus 40 that is defective for transformation and the production of infectious virions.

Authors:  K W Peden; S L Spence; L C Tack; C A Cartwright; A Srinivasan; J M Pipas
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 6.  Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes.

Authors:  S S Tevethia
Journal:  Mol Biol Med       Date:  1990-02

7.  Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.

Authors:  P L Earl; A W Hügin; B Moss
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

8.  Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7.

Authors:  G Meneguzzi; C Cerni; M P Kieny; R Lathe
Journal:  Virology       Date:  1991-03       Impact factor: 3.616

9.  DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood.

Authors:  D J Bergsagel; M J Finegold; J S Butel; W J Kupsky; R L Garcea
Journal:  N Engl J Med       Date:  1992-04-09       Impact factor: 91.245

10.  Transformation of a continuous rat embryo fibroblast cell line requires three separate domains of simian virus 40 large T antigen.

Authors:  J Zhu; P W Rice; L Gorsch; M Abate; C N Cole
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more
  8 in total

1.  Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.

Authors:  Mohamed S Arredouani; Stephanie S Tseng-Rogenski; Brent K Hollenbeck; June Escara-Wilke; Karen R Leander; Deborah Defeo-Jones; Clara Hwang; Martin G Sanda
Journal:  Prostate       Date:  2010-06-15       Impact factor: 4.104

2.  An anti-nucleic acid antibody delivers antigen to the cross-presentation pathway in dendritic cells and potentiates therapeutic antitumor effects.

Authors:  Chuong D Pham; Min-Yeong Woo; Yong-Sung Kim; Sun Park; Myung-Hee Kwon
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

3.  CD8+ T-cell cross-competition is governed by peptide-MHC class I stability.

Authors:  Ian Galea; Jana Stasakova; Melanie S Dunscombe; Christian H Ottensmeier; Tim Elliott; Stephen M Thirdborough
Journal:  Eur J Immunol       Date:  2011-11-28       Impact factor: 5.532

4.  A safety-modified SV40 Tag developed for human cancer immunotherapy.

Authors:  Stephanie S Tseng-Rogenski; Mohamed S Arredouani; June F Escara-Wilke; Yilin C Neeley; Michael J Imperiale; Martin G Sanda
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

Review 5.  Malignant pleural mesothelioma.

Authors:  H L Kindler
Journal:  Curr Treat Options Oncol       Date:  2000-10

Review 6.  Advances in the management of malignant mesothelioma.

Authors:  Mazen Y Khalil; Marissa Mapa; Hyung Ju C Shin; Dong M Shin
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.945

7.  Simian virus 40 in humans.

Authors:  Fernanda Martini; Alfredo Corallini; Veronica Balatti; Silvia Sabbioni; Cecilia Pancaldi; Mauro Tognon
Journal:  Infect Agent Cancer       Date:  2007-07-09       Impact factor: 2.965

Review 8.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.